DENVER, CO--(Marketwire - Nov 14, 2012) - Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a biopharmaceutical company focused on the development of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications including Type 1 diabetes, recognizes the publication of proof of concept pre-clinical data supporting the advancement of AAT as a pivotal therapy for a range of clinically important conditions, including Type 1 diabetes.
Announced by the Israeli Company, Kamada Limited, data from studies performed by Dr. Eli Lewis suggests that AAT can shorten the duration, severity and frequency of adverse events associated with certain diseases. Along with Dr. Leland Shapiro of the University of Colorado, a co-founder of Omni Bio, and Dr. Charles Dinarello, Chief Scientific Officer of Omni Bio, Dr. Lewis is a co-inventor on US and foreign patent applications licensed by Omni Bio from the University of Colorado for the methods and use of AAT for the treatment and prevention of graft rejection, and reduction of and treatment for graft versus host disease (GVHD), a severe and sometimes fatal side-effect of certain transplantations.
Omni Bio is also the exclusive licensee to an issued U.S. patent for treating diabetes using AAT. Dr. Leland Shapiro is the inventor of this technology and the patent is owned by Bio Holding, Inc., a private company that is majority-owned by Dr. Shapiro. In addition, Omni Bio continues to support a clinical study at the Barbara Davis Center for Childhood Diabetes directed to using AAT to treat early onset Type 1 diabetes.
Dr. Lewis' research findings further highlight the opportunities currently being developed by Omni Bio for leveraging sponsored research and pursuing collaborations with existing AAT manufacturers.
Additional information concerning Dr. Lewis' research findings can be found at http://www.kamada.com/press_item.php?ID=27
About Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical (www.omnibiopharma.com) is a biopharmaceutical company that is focused on AAT and on developing new recombinant versions of AAT that can be applied to the treatment of a broad range of indications including, for example, Type 1 diabetes, graft rejection, graft versus host disease (GVHD), cardiac conditions and inflammatory bowel diseases. Since its formation, Omni Bio has supported research using animal models and human clinical studies that demonstrate that AAT is a promising agent for ameliorating these conditions.
Some of the statements made in this press release are forward-looking statements that reflect management's current views and expectations with respect to future events. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. These risks and uncertainties are based on a number of factors, including but not limited to the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2012. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.